Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Focused Shock Wave Therapy Before and After Botulinum Toxin in Post-Stroke Spastic Equinovarus Foot
NCT07758322Active, not recruiting
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Randomised, single-blind trial of botulinum toxin type A in spasticity and spastic equinovarus foot (SEVF) (3 arms). Primary endpoint: Modified Ashworth Scale at 54 weeks. Started Oct 2024; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
spasticityspastic equinovarus foot (SEVF)
Beyond the preview
Go deeper on NCT07758322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07758322.